Medical oncologist focused on GU tumors Fundación Jiménez Díaz Hospital
Madrid - Pamplona
Joined September 2011
- Tweets2.1K
- Following285
- Followers315
- Likes2.3K
Imanol Martínez Salas retweeted
📢 #ESMO26 concomitant paper - Capivasertib plus abiraterone in PTEN-deficient de novo metastatic hormone-sensitive prostate cancer: updated survival analysis from CAPItello-281.
🔗shorturl.at/c6tvw
@Daniel_J_George
Imanol Martínez Salas retweeted
Himalayas-1: Rinzimetostat, an Allosteric PRC2 Inhibitor, + Daro: 🌎 Ph 3 RC in mCRPC Previously Treated with Abiraterone @urotoday #ESMO26 @quimmateo
📌n=600
📌1:1 to rinzimetostat + Daro vs physician’s choice of ARPI or docetaxel
📌Prim EP: rPFS
📌Sec EP: OS
Imanol Martínez Salas retweeted
ESMO 2026 - presidential LBA | VOLGA Phase III –
Perioperative Durvalumab + Enfortumab Vedotin (EV) in cisplatin-ineligible/refusing patients:
📊 EV + Durva vs Control
• 2-year EFS: 64% vs 45% (HR 0.51; p<0.0001)
• 2-year OS: 78% vs 69% (HR 0.58; p=0.0027)
• pCR: 45% vs 10%
Adding tremelimumab improved EFS (HR 0.61) but no significant OS benefit yet, with higher grade 3/4 toxicity (42% vs 30%).
🔥can this stop the need of post op EV ? Probably yes . New SOC 🙂👍
Looking forward the full datasets @OncBrothers
@OncoAlert @myESMO
#ESMO26 #VOLGA #BladderCancer
Imanol Martínez Salas retweeted
Daro + ADT and docetaxel in mHSPC: RW Evidence from the TRIDA Study of SOGUG 🇪🇸 #ESMO26 @urotoday @Ricardo62949193
mFU: 11 mos
📌16.2% progressed to CRPC
📌mOS NR, 18 mo probability of survival: 86.5%
📌48.5% PSA <= 0.2
📌83.3% disease control
📌Similar safety to ARASENS
Imanol Martínez Salas retweeted
🚨 #ESMO26 GU Oncology — Top picks by OncoAlert 🎯
#BladderCancer : VOLGA, KEYNOTE-B15, ENERGIZE, KEYNOTE-866
#ProstateCancer: DASL-HiCaP, CAPItello-281, PROTEUS
#KidneyCancer: LITESPARK-011 & -012, ivonescimab, PE-PE, SWOG S2200, XmAb819
Our Participating Faculty
@DrChoueiri, @tompowles1, @apolo_andrea, @neerajaiims, @montypal, @Silke_Gillessen, @AOmlin, @brian_rini, @PGrivasMDPhD, @TiansterZhang, @amerseburger , @DrDanielHeng, @HHammersMD, @scocmem, @AndreaNecchi , @AmandaNizamMD, @drenriquegrande, @nataliagandur
@AlbigesL, @cdanicas, @declangmurphy, @seanmmcbride, @shilpaonc, @DrRanaMcKay, @scserendipity1, @DrYukselUrun , @ravikanesvaran , @BraunMDPhD, @EfstathiouEleni, @mzugman , @crisbergerot, @ElisaAgostinett, @to_be_elizabeth, @MarioBalsaMD, @BRicciutiMD, @HHorinouchi, @UOzkerim, @p_ciracimd, @DrMirallas , @sonpavde , @Dr_Oncologista
Imanol Martínez Salas retweeted
Worth reading: a sharp analysis of PROTEUS trial results by @DrSpratticus 👇
nature.com/articles/s41571-0…
Imanol Martínez Salas retweeted
🚨 In advanced #ProstateCancer, BRCA status correlates with response to AR-directed therapy 🚨
@CRC_AACR @AACR, pooled analysis of 5 randomized ARPI trials (apalutamide or abiraterone):
👥 608 pts on ARPI-based regimens, HRR status by tissue or plasma sequencing
📊 Retrospective pooled biomarker analysis, endpoints rPFS and OS
✅ BRCA-altered pts did worse on ARPIs:
Progression HR 1.8 (1.16-2.79) p=0.009,
Mortality HR 1.6 (1.02-2.34) p=0.038
✅ HRR-altered (any) had shorter
rPFS, HR 1.7 (1.2-2.3), p=0.001
✅ HRR-altered men still benefit from intensifying: adding ARPI to ADT prolonged:
rPFS HR 0.42 (0.2-0.89)
OS HR 0.45 (0.23-0.91)
⚠️ Retrospective, ARPIs limited to Apa/Abi. Hypothesis-generating for combinations
🎯 HRR and especially BRCA alterations = aggressive biology, still, they benefit from ARPi benefits
🔗 doi.org/10.1158/2767-9764.CR…
@UroOnc @PCFnews @PCF_Science @SUO_YUO @UrologyTimes @urotoday
Imanol Martínez Salas retweeted
More evidence for Nectin4 as a biomarker for EV in @EUplatinum
In 1L EV+P, high Nectin4 RNA expression was associated with ⬆️ORR and OS but this was not seen with Pembro alone.
Data on membranous expression & amplification might be useful.
@OncoAlert
europeanurology.com/article/…
Imanol Martínez Salas retweeted
How does bladder cancer spread? 🔬 New work published today in @Nature uses clonal tracing to show that new metastases are predominantly seeded by an earlier metastasis, potentially highlighting a critical window for intervention with metastasis-directed therapies. @fredhutch
Ever wonder how heterogeneity defines bladder cancer subtypes?
Ha and Hsieh Lab postdoctoral fellows @pushpa_itagi and Samantha Schuster @fredhutch did, leading to a deep study of bladder cancer clonality, evolution, and heterogeneity published @Nature
nature.com/articles/s41586-0…
Imanol Martínez Salas retweeted
Could NECTIN4 localization—and not just expression—help us identify which patients are most likely to benefit from enfortumab vedotin?
Article 📰
buff.ly/ZoHD2ie
Integrating NECTIN4 Amplification With Membranous Nectin-4 Expression to Develop a Scoring System for Predicting Enfortumab Vedotin Response in Urothelial Carcinoma
In this retrospective analysis of 179 EV-treated patients with metastatic urothelial carcinoma, high membranous NECTIN4 🧬 expression predicted response, PFS, and OS, whereas cytoplasmic expression did not. NECTIN4 amplification identified a particularly favorable subgroup.
➡️ An integrated model combining amplification and membranous expression further stratified response and survival, suggesting a potential biomarker framework for optimizing EV selection. #BladderCancer
@niklas_kluemper, @piapiacere, @Richard_Weiten, @susanne_fussel, @jcasusce, @KuppeChristoph, @JoshMeeks, @bonnie_choy, @braegelmannlab, @HolzelMichael, @ViktorGruenwald, @Markuseckstein3
@DrChoueiri, @tompowles1, @apolo_andrea, @neerajaiims, @montypal, @Silke_Gillessen, @AOmlin, @brian_rini, @PGrivasMDPhD, @TiansterZhang, @AlbigesL, @cdanicas, @amerseburger, @sonpavde, @DrDanielHeng, @declangmurphy, @seanmmcbride, @HHammersMD, @shilpaonc, @DrRanaMcKay, @scserendipity1, @DrYukselUrun, @scocmem, @AmandaNizamMD, @drenriquegrande, @BraunMDPhD, @EfstathiouEleni, @nataliagandur, @realbowtiedoc, @FernandoOnco, @ElisaAgostinett, @to_be_elizabeth, @MarioBalsaMD
Imanol Martínez Salas retweeted
🚨 8 mutational processes explain 85% of primary #prostatecancer genomes 🚨
@Nature, Pan Prostate Cancer Group:
👥 959 primary tumours w/ WGS, median f/u 7 yrs
📊 SBS + indel + copy number + 6 new complex SV signatures combined into 8 integrated footprints
✅ 4 of them, in 37% of tumours, predicted metastasis independent of age, Gleason, stage, TMB (HRs 4.05 to 7.71)
✅ The same signatures analyzed one at a time predicted nothing, need to know the dominant cluster!
✅ In mCRPC, a replication-stress footprint predicted ARPI over taxane: HR 0.21 for treatment failure
⚠️ Retrospective, ARPI signal rests on 25 pts, WGS of course not routine practice
🎯 Bottom line: we keep asking is it HRD, is it BRCA. Under 3% of primary PCa answer yes. Integrate four kinds of variation instead and you stratify 85% of genomes.
🔗 doi.org/10.1038/s41586-026-1…
@AmerUrological @UroOnc @PCFnews @PCF_Science @SUO_YUO @UroOnc
Imanol Martínez Salas retweeted
⚡️ Real-world quality of life outcomes in metastatic urothelial cancer treated with EV + pembrolizumab: QoL improved in responders, but deteriorated in patients who progressed.
Efficacy and patient-reported outcomes tell different stories — both matter for shared decision-making.
ascopubs.org/doi/10.1200/OA-…
@AndreaNecchi @JCO_ASCO
#BladderCancer
Imanol Martínez Salas retweeted
⚡️ VESPER trial: basal molecular subtype is an independent prognostic factor for OS in MIBC treated with neoadjuvant chemotherapy, regardless of the regimen used.
Molecular subtyping beyond clinical staging — increasingly relevant in treatment decision-making.
euoncology.europeanurology.c…
#BladderCancer @EurUrolOncol
Imanol Martínez Salas retweeted
An interesting paper in @JournalCancer provides supportive, hypothesis-strengthening evidence for DFS as a trial-level surrogate, but not definitive validation—especially not for contemporary adjuvant immunotherapy or HIF-2–based combinations. acsjournals.onlinelibrary.wi…
The work builds on @Wanling50578056 from 2018
pubmed.ncbi.nlm.nih.gov/2926…
Imanol Martínez Salas retweeted
Real-world adjuvant nivolumab in PD-L1 positive muscle-invasive #UrothelialCarcinoma. Aurea Molina Diaz, MD joins @zklaassen_md to discuss PrInCIS-NIADY, a nationwide Spanish real-world study of adjuvant nivolumab in patients with high-risk PD-L1-positive muscle-invasive urothelial carcinoma following surgery. #WatchNow > bit.ly/4vF3dqr
Imanol Martínez Salas retweeted
Genomic risk stratification in metastatic hormone-sensitive #ProstateCancer with STRATOS-P. @mwschoen @SLU_Official joins @TDorffOnc @cityofhope to discuss STRATOS-P, a genomic risk classification derived from next-generation sequencing data on over 2,000 veterans with metastatic hormone-sensitive prostate cancer. Analysis of more than 300 genes identified 16 prognostic for overall survival, with alterations in tumor suppressor genes including TP53, PTEN, and RB1 defining the unfavorable risk group. #WatchNow > bit.ly/4b22WGW
Imanol Martínez Salas retweeted
MTAP loss in bladder cancer: 26.4% prevalence — one of the highest across solid tumors (>500K specimens).
Important: CDKN2A loss is not a reliable proxy. 33.7% of CDKN2A-deleted tumors do NOT have MTAP loss — a critical distinction for patient selection in PRMT5/MAT2A inhibitor trials.
ascopubs.org/doi/full/10.120…
#BladderCancer
Imanol Martínez Salas retweeted
📌Response-guided bladder preservation in #MIBC
Standardised cCR (TURBT biopsies + urine cytology + imaging) as a robust composite biomarker to guide these strategies.
Prospective trials (EV-309, NEO-BLAST) will be crucial.
@OncoAlert @EUplatinum
europeanurology.com/article/…
